FrancophonIA/ELRC3.0 huggingface dataset:
English: Cardiovascular safety assessment study in subjects with and without a history of psychiatric disorder The cardiovascular (CV) safety of CHAMPIX was evaluated in the Study in Subjects with and without a History of Psychiatric Disorder (parent study; see section 5.1 - Neuropsychiatric safety) and its nontreatment extension, the Cardiovascular Safety Assessment Study, which enrolled 4595 of the 6293 subjects who completed the parent study (N=8058) and followed them through week 52.
Slovenian: Študija za oceno srčnožilne varnosti pri preskušancih s psihiatrično motnjo v anamnezi ali brez nje Srčnožilno varnost zdravila CHAMPIX so ovrednotili v Študiji pri preskušancih s psihiatrično motnjo v anamnezi ali brez nje (matična študija; glejte poglavje 5.1 - Nevropsihiatrična varnost) in v podaljšanju te študije brez zdravljenja, imenovanem Študija za oceno srčnožilne varnosti, v katero so vključili 4.595 od 6.293 preskušancev, ki so zaključili matično študijo (n = 8.058), in jih spremljali do vključno 52. tedna.
English: Single and multiple-dose pharmacokinetics of varenicline have been investigated in paediatric patients aged 12 to 17 years old (inclusive) and were approximately dose-proportional over the 0.5 mg to 2 mg daily dose range studied.
Slovenian: Farmakokinetiko vareniklina po enkratnem in večkratnem odmerjanju so raziskovali pri pediatričnih bolnikih, starih od 12 do (vključno) 17 let, ta farmakokinetika pa je bila približno sorazmerna odmerku pri odmerkih v območju od 0,5 mg do 2 mg na dan, ki so jih raziskovali.
English: These are equivalent to an estimated increase of 6.5 MACE events and 6.3 MACE events per 1,000 patient-years, respectively of exposure.
Slovenian: To je enakovredno ocenjenemu povečanju števila dogodkov MACE, ki znaša 6,5 na 1.000 bolnikov-let med zdravljenjem, in 6,3 na 1.000 bolnikov-let v obdobju do 30 dni po zdravljenju.
English: The treatment discontinuation rate due to adverse reactions was 11.4% for varenicline compared with 9.7% for placebo.
Slovenian: Delež prekinitev zdravljenja zaradi neželenih učinkov je bil 11,4 % pri bolnikih, ki so dobivali vareniklin, in 9,7 % pri tistih, ki so dobivali placebo.
English: Patient reported craving, withdrawal and reinforcing effects of smoking Across both Studies 1 and 2 during active treatment, craving and withdrawal were significantly reduced in patients randomised to CHAMPIX in comparison with placebo.
Slovenian: Bolniki so navajali hlepenje, odtegnitvene učinke in okrepitvene učinke kajenja V obeh študijah, študiji 1 in študiji 2, je bilo med uporabo učinkovine hlepenja in odtegnitvenih učinkov statistično pomembno manj med bolniki, ki so bili randomizirani na zdravilo CHAMPIX, kot med tistimi, ki so dobivali placebo.
English: Champix is for oral use.
Slovenian: Zdravilo Champix je namenjeno za peroralno uporabo.
English: CHAMPIX comes as a white tablet (0.5 mg) and a light blue tablet (1 mg).
Slovenian: Zdravilo CHAMPIX je na voljo v obliki belih tablet (0,5 mg) in svetlomodrih tablet (1 mg).
English: Liver function test abnormal
Slovenian: Preiskave Pogosti nenormalni izvidi testov jetrne funkcije
English: The primary safety endpoint was a composite of the following neuropsychiatric (NPS) adverse events: severe events of anxiety, depression, feeling abnormal, or hostility, and/or moderate or severe events of agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behaviour or completed suicide.
Slovenian: Glavni opazovani dogodek varnosti je bil sestavljen iz naslednjih nevropsihiatričnih (NPSNeuropsychiatric) neželenih dogodkov: huda anksioznost, depresija, nenormalno počutje ali sovražnost in/ali zmerna do huda agitacija, agresija, blodnje, halucinacije, morilske misli, manija, panika, paranoja, psihoza, samomorilne misli, samomorilno vedenje ali samomor.
English: Subjects with cardiovascular disease
Slovenian: Preskušanci s srčnožilnimi boleznimi
English: The key cardiovascular safety analysis included occurrence and timing of a composite endpoint of Major Adverse Cardiovascular Events (MACE), defined as cardiovascular death, nonfatal MI, and nonfatal stroke.
Slovenian: Ključna analiza srčnožilne varnosti je vključevala pojavljanje in čas pojavljanja sestavljenega opazovanega dogodka izrazitejši srčnožilni neželeni učinki (MACE - Major Adverse Cardiovascular Events), ki so definirani kot srčnožilna smrt, miokardni infarkt brez smrtnega izida in možganska kap brez smrtnega izida.
English: In addition, the table shows the subset of the composite NPS AE endpoint of severe intensity:
Slovenian: Poleg tega preglednica prikazuje tudi podskupino hudih AE sestavljenega opazovanega dogodka NPS:
English: In a smoking cessation clinical trial, neuropsychiatric adverse events were reported more frequently in patients with a history of psychiatric disorders compared to those without a history of psychiatric disorders, regardless of treatment (see section 5.1).
Slovenian: V kliničnem preskušanju prenehanja kajenja so o nevropsihiatričnih neželenih dogodkih pogosteje poročali pri bolnikih s psihiatričnimi motnjami v anamnezi kot pri bolnikih brez psihiatričnih motenj v anamnezi, ne glede na zdravljenje (glejte poglavje 5.1).
English: What CHAMPIX is and what it is used for 2.
Slovenian: Kaj je zdravilo CHAMPIX in za kaj ga uporabljamo
English: Anxiety disorders and symptoms Depressed mood disorders and disturbances Mood disorders and disturbances NEC*
Slovenian: anksiozne motnje in simptomi depresivne motnje razpoloženja motnje razpoloženja NEC* * NEC = niso razvrščene drugje
English: Electrophysiology studies in vitro and neurochemical studies in vivo have shown that varenicline binds to the α4β2 neuronal nicotinic acetylcholine receptors and stimulates receptor-mediated activity, but at a significantly lower level than nicotine.
Slovenian: Elektrofiziološke študije in vitro in nevrokemične študije in vivo so pokazale, da se vareniklin veže na α4β2 nevronske nikotinske holinergične receptorje (nAchR) in stimulira receptorsko posredovano delovanje, vendar bistveno manj kot nikotin.
English: * NEC = Not Elsewhere Classified Counts (percentages) corresponds to the number of patients reporting the event
Slovenian: Številke (odstotki) ustrezajo številu bolnikov, ki so poročali o dogodku.
English: CA = continuous abstinence rate; CI = confidence interval; NRT=Nicotine replacement therapy patch
Slovenian: CA stopnja trajne abstinence; IZ interval zaupanja; NRT nadomestno zdravljenje z nikotinskim obližem
English: Chest pain, fatigue
Slovenian: • bolečina v prsnem košu, utrujenost
English: Subjects with mild-moderate chronic obstructive pulmonary disease (COPD) The efficacy and safety of CHAMPIX (1 mg twice daily) for smoking cessation in subjects with mild-moderate COPD was demonstrated in a randomised double-blind placebo-controlled clinical trial.
Slovenian: Osebe z blago do zmerno kronično obstrukcijsko pljučno boleznijo (KOPB) Učinkovitost in varnost uporabe zdravila CHAMPIX (1 mg dvakrat na dan) za opustitev kajenja pri osebah z blago do zmerno KOPB so dokazali v randomiziranem, dvojno slepem, s placebom nadzorovanim kliničnem preskušanju.
English: In vitro studies demonstrate that varenicline does not inhibit human renal transport proteins at therapeutic concentrations.
Slovenian: Študije in vitro so pokazale, da vareniklin v terapevtskih koncentracijah pri človeku ne zavira transportnih beljakovin v ledvicah.
English: In patients with a high risk of relapse, dose tapering may be considered (see section 4.4).
Slovenian: Pri bolnikih z visokim tveganjem za ponoven začetek kajenja lahko razmislimo o postopnem zmanjševanju odmerka (glejte poglavje 4.4).
English: Two of the studies found no difference in risk of neuropsychiatric hospitalisations between varenicline users and nicotine patch users (Hazard Ratio [HR] 1.14; 95% Confidence Interval [CI]: 0.56-2.34 in the first study, and 0.76; 95% CI: 0.40-1.46 in the second study).
Slovenian: V dveh od teh študij niso ugotovili razlike v tveganju za nevropsihiatrične hospitalizacije med uporabniki vareniklina in uporabniki nikotinskih obližev (razmerje ogroženosti (HR - Hazard Ratio) 1,14; 95 % interval zaupanja (IZ): 0,56-2,34 v prvi študiji, in 0,76; 95 % IZ: 0,40-1,46 v drugi študiji).
English: A large randomised, double-blind, active and placebo-controlled study was conducted to compare the risk of serious neuropsychiatric events in patients with and without a history of psychiatric disorder treated for smoking cessation with varenicline, bupropion, nicotine replacement therapy patch (NRT) or placebo.
Slovenian: Opravili so obsežno randomizirano, dvojno slepo, z učinkovino in placebom nadzorovano študijo za primerjavo tveganja za pojav resnih nevropsihiatričnih dogodkov pri bolnikih s psihiatrično motnjo v anamnezi ali brez nje, zdravljenih za prenehanje kajenja z vareniklinom, bupropionom, nadomestnim zdravljenjem z nikotinskim obližem (NRT - Nicotine Replacement Therapy) ali placebom.
English: The effects of changes in your body resulting from stopping smoking, with or without treatment with CHAMPIX, may alter the way other medicines work.
Slovenian: Spremembe, ki jih v telesu povzroči opustitev kajenja, če zdravilo CHAMPIX uporabljate ali ne, lahko vplivajo na delovanje drugih zdravil.
English: Also, in human hepatocytes in vitro, varenicline was shown to not induce the activity of cytochrome P450 enzymes 1A2 and 3A4.
Slovenian: Prav tako je bilo v človeških hepatocitih in vitro dokazano, da vareniklin ne inducira aktivnosti encimov 1A2 in 3A4 citokroma P450.
English: The most commonly reported adverse events in subjects treated with varenicline in this study were similar to those observed in premarketing studies.
Slovenian: V tej študiji so bili najpogosteje poročani neželeni dogodki pri preskušancih, zdravljenih z vareniklinom, podobni tistim, ugotovljenim v študijah pred začetkom trženja.
English: Two thousand six hundred nineteen (2619) patients received CHAMPIX 1 mg BID (titrated during the first week), 669 patients received bupropion 150 mg BID (also titrated) and 684 patients received placebo.
Slovenian: Dva tisoč šeststo devetnajst (2.619) bolnikov je dobivalo zdravilo CHAMPIX v odmerku 1 mg dvakrat na dan (titriran med prvim tednom), 669 bolnikov je dobivalo bupropion v odmerku 150 mg dvakrat na dan (prav tako titriran), 684 bolnikov pa je dobivalo placebo.
English: Four observational studies, each including 10,000 to 30,000 users of varenicline in the adjusted analyses, compared the risk of serious neuropsychiatric events, including neuropsychiatric hospitalizations and fatal and non-fatal self-harm, in patients treated with varenicline versus patients prescribed NRT or bupropion.
Slovenian: V štirih opazovalnih študijah, od katerih je vsaka v prilagojene analize vključevala od 10.000 do 30.000 uporabnikov vareniklina, so pri bolnikih, zdravljenih z vareniklinom, v primerjavi z bolniki, ki so prejemali NRT ali bupropion, primerjali tveganje za pojav resnih nevropsihiatričnih dogodkov, vključno z nevropsihiatričnimi hospitalizacijami, samopoškodovanjem s smrtnim izidom ter brez smrtnega izida.
English: Some people have reported seizures while taking CHAMPIX.
Slovenian: Nekateri ljudje so poročali o epileptičnih napadih med jemanjem zdravila CHAMPIX.
English: In patients with severe renal impairment, the concomitant use of cimetidine and varenicline should be avoided.
Slovenian: Pri bolnikih s hudo okvaro ledvic se je treba sočasni uporabi cimetidina in vareniklina izogniti.
English: Varenicline binds with high affinity and selectivity at the α4β2 neuronal nicotinic acetylcholine receptors, where it acts as a partial agonist - a compound that has both agonist activity, with lower intrinsic efficacy than nicotine, and antagonist activities in the presence of nicotine.
Slovenian: Vareniklin se z veliko afiniteto in selektivnostjo veže na α4β2 nevronske nikotinske holinergične receptorje in na njih deluje kot delni agonist - spojina, ki ima tako agonistično delovanje (z manjšo intrinzično učinkovitostjo kot nikotin) kot antagonistično delovanje v prisotnosti nikotina.
English: Analyses of Clinical Trials:
Slovenian: Analize kliničnih preskušanj
English: CHAMPIX vs. placebo p < 0.0001
Slovenian: CHAMPIX v primerjavi s placebom p < 0,0001
English: From day 1 to day 3, you should take one white CHAMPIX 0.5 mg film-coated tablet once a day.
Slovenian: 1. do 3. dan Od 1. do 3. dne vzemite eno belo filmsko obloženo tableto CHAMPIX 0,5 mg enkrat na dan.
English: In the offspring of pregnant rats treated with varenicline there were decreases in fertility and increases in the auditory startle response (see section 4.6).
Slovenian: Pri mladičih podgan, ki so dobivale vareniklin, so ugotovili manjšo plodnost in močnejšo reakcijo na slušni dražljaj (glejte poglavje 4.6).
English: If you stop taking CHAMPIX
Slovenian: Če ste prenehali jemati zdravilo CHAMPIX
English: OTHER sun as symbol moon as symbol
Slovenian: sonce kot simbol luna kot simbol
English: There were similar rates of all-cause mortality (CHAMPIX 6 [0.14%]; placebo 7 [0.25%]) and cardiovascular mortality (CHAMPIX 2 [0.05%]; placebo 2 [0.07%]) in the CHAMPIX arms compared with the placebo arms in the meta-analysis.
Slovenian: V meta analizi sta bili stopnja umrljivosti iz vseh vzrokov (CHAMPIX 6 [0,14 %]; placebo 7 [0,25 %]) in stopnja srčnožilne umrljivosti (CHAMPIX 2 [0,05 %]; placebo 2 [0,07 %]) podobni v skupinah, ki so prejemale zdravilo CHAMPIX, in v skupinah, ki so prejemale placebo.
English: Treatment initiation packs:
Slovenian: Pakiranja za začetek zdravljenja:
English: Overall, there was no worsening of schizophrenia in either treatment group as measured by psychiatric scales and there were no overall changes in extra-pyramidal signs.
Slovenian: Pri nobeni od preskušanih skupin se shizofrenija ni poslabšala, upoštevajoč kriterije psihiatričnih lestvic; prav tako ni bilo sprememb glede ekstrapiramidnih znakov.
English: CHAMPIX is not recommended in paediatric patients because its efficacy in this population was not demonstrated (see sections 4.2 and 5.1).
Slovenian: Zdravilo CHAMPIX pri pediatričnih bolnikih ni priporočljivo, ker njegova učinkovitost pri tej populaciji ni bila dokazana (glejte poglavji 4.2 in 5.1).
English: The 4W-CQR (weeks 9 through 12) and CA rate (weeks 9 through 52) from studies 1 and 2 are included in the following table:
Slovenian: 4W-CQR (od 9. do vključno 12. tedna) in odstotek CA (od 9. do vključno 52. tedna) iz študij 1 in 2 zajema spodnja preglednica:
English: Patients should then continue taking CHAMPIX for an additional 12 weeks for a total of 24 weeks of treatment (see section 5.1).
Slovenian: Nato morajo z jemanjem zdravila CHAMPIX nadaljevati še dodatnih 12 tednov, tako da je skupno trajanje zdravljenja 24 tednov (glejte poglavje 5.1).
English: CHAMPIX is a medicine which is used in adults to help them stop smoking.
Slovenian: Zdravilo CHAMPIX je zdravilo, ki ga uporabljamo kot pomoč pri opustitvi kajenja pri odraslih.
English: CHAMPIX can help to relieve the craving and withdrawal symptoms associated with stopping smoking.
Slovenian: Zdravilo CHAMPIX lahko pomaga ublažiti željo po kajenju in odtegnitvene simptome, ki spremljajo opustitev kajenja.
English: During the active treatment period, the incidence of suicide-related events was similar between the varenicline-treated and the placebo-treated subjects (11 vs. 9.3%, respectively).
Slovenian: V obdobju, v katerem so prejemali zdravilo, je bila pogostnost s samomorom povezanih dogodkov podobna med preskušanci, ki so prejemali vareniklin, ter preskušanci, ki so prejemali placebo (11 v primerjavi z 9,3 %).
English: CHAMPIX was evaluated in a double-blind, placebo-controlled trial of 494 patients who had made a previous attempt to quit smoking with CHAMPIX, and either did not succeed in quitting or relapsed after treatment.
Slovenian: Študija pri preskušancih, ki so bili ponovno zdravljeni z zdravilom CHAMPIX Zdravilo CHAMPIX so ovrednotili v dvojno slepem, s placebom nadzorovanem preskušanju pri 494 bolnikih, ki so z zdravilom CHAMPIX že poskusili opustiti kajenje in pri tem niso uspeli ali so po zdravljenju ponovno začeli kaditi.
English: Therefore, varenicline is unlikely to alter the pharmacokinetics of compounds that are primarily metabolised by cytochrome P450 enzymes.
Slovenian: Zato ni verjetno, da bi vareniklin spremenil farmakokinetiko snovi, katerih presnova poteka predvsem z encimi citokroma P450.
English: Neuropsychiatric symptoms
Slovenian: Nevropsihiatrični simptomi
English: The primary endpoint for CHAMPIX demonstrated statistical superiority to bupropion and placebo.
Slovenian: Glavni opazovani dogodek je statistično pokazal, da je zdravilo CHAMPIX učinkovitejše od bupropiona in placeba.
English: For patients who have successfully stopped smoking at the end of 12 weeks, an additional course of 12 weeks treatment with CHAMPIX at 1 mg twice daily may be considered for the maintenance of abstinence (see section 5.1).
Slovenian: Pri bolnikih, ki po 12 tednih uspešno opustijo kajenje, se lahko odločimo za nadaljnji 12-tedenski ciklus zdravljenja z zdravilom CHAMPIX v odmerku 1 mg dvakrat na dan za vzdrževanje abstinence (glejte poglavje 5.1).
English: Neuropsychiatric Safety Meta-analyses and Observational Studies:
Slovenian: Opazovalne študije in meta analize nevropsihiatrične varnosti:
English: A key secondary endpoint was the continuous abstinence (CA) rate for week 13 through week 52.
Slovenian: Ključni sekundarni opazovani dogodek je bil odstotek trajne abstinence (CA) od 13. do vključno 52. tedna.
English: In rodents, varenicline is transferred through the placenta and excreted in milk.
Slovenian: Pri glodalcih vareniklin prehaja skozi placento in se izloča v mleko.
English: The primary study endpoint was the CO-confirmed continuous abstinence rate from week 13 through week 24 in the double-blind treatment phase.
Slovenian: Glavni opazovani dogodek študije je bil s CO preverjeni odstotek trajne abstinence od 13. do vključno 24. tedna v dvojno slepi fazi zdravljenja.
English: A meta-analysis of 5 randomised, double-blind, placebo controlled trials, including 1907 patients (1130 varenicline, 777 placebo), was conducted to assess suicidal ideation and behaviour as reported on the Columbia-Suicide Severity Rating Scale (C-SSRS).
Slovenian: Opravili so meta analizo 5 randomiziranih, dvojno slepih, s placebom nadzorovanih preskušanj, ki so vključevala 1.907 bolnikov (1.130 vareniklin, 777 placebo), s katero so ocenili samomorilne misli in vedenje, kot so o njiju poročali po lestvici C-SSRS.
English: In this study, infants exposed to CHAMPIX in utero as compared to infants born to mothers who smoked during pregnancy had lower rates of congenital malformations (3.6% vs 4.3%), stillbirth (0.3% vs 0.5%), preterm birth (7.5% vs 7.9%), small for gestational age (12.5% vs 17.1%), and premature rupture of membrane (3.6% vs 5.4%).
Slovenian: V tej študiji je bil pri dojenčkih, ki so bili zdravilu CHAMPIX izpostavljeni in utero, v primerjavi z dojenčki, rojenimi materam, ki so med nosečnostjo kadile, manjši delež prirojenih malformacij (3,6 % v primerjavi s 4,3 %), manjši delež mrtvorojenosti (0,3 % v primerjavi z 0,5 %), manjši delež nedonošenčkov (7,5 % v primerjavi s 7,9 %), manjši delež primerov dojenčkov premajhnih za gestacijsko starost (12,5 % v primerjavi s 17,1 %) in manjši delež primerov prezgodnjega razpoka plodnega mehurja (3,6 % v primerjavi s
English: Gradual approach to quitting smoking
Slovenian: Postopna opustitev kajenja
English: Serious side effects of either an uncommon or rare frequency have occurred in people attempting to quit smoking with CHAMPIX: seizure, stroke, heart attack, suicidal thoughts, loss of contact with reality and unable to think or judge clearly (psychosis), changes in thinking or behaviour (such as aggression and abnormal behaviour).
Slovenian: Pri ljudeh, ki so poskusili prenehati kaditi z zdravilom CHAMPIX, so se pojavili resni neželeni učinki z občasno ali redko pogostnostjo: epileptični napad, možganska kap, srčni infarkt, samomorilne misli, izguba stika z realnostjo in nezmožnost jasnega razmišljanja ali presojanja (psihoza), spremembe mišljenja ali vedenja (kot sta agresija in nenormalno vedenje).
English: When 0.5 mg twice daily was given, steady-state daily exposure of varenicline was, on average, higher (by approximately 40%) in adolescent patients with bodyweight ≤ 55 kg compared to that noted in the adult population.
Slovenian: Ko so zdravilo v odmerku 0,5 mg dajali dvakrat na dan, je bila dnevna izpostavljenost vareniklinu v stanju dinamičnega ravnovesja pri mladostnikih s telesno maso ≤ 55 kg v povprečju večja (za približno 40 %) v primerjavi z izpostavljenostjo, ki so jo ugotovili pri odrasli populaciji.
English: CHAMPIX smoking cessation studies have provided data in patients with a history of psychiatric disorders (see section 5.1).
Slovenian: Na voljo so podatki iz študij prenehanja kajenja z zdravilom CHAMPIX pri bolnikih s psihiatričnimi motnjami v anamnezi (glejte poglavje 5.1).
English: Additionally, a small number of MACE occurred up to 30 days after treatment (CHAMPIX 13 [0.31%]; placebo 6 [0.21%]).
Slovenian: Poleg tega je do majhnega števila primerov MACE (CHAMPIX 13 [0,31 %]; placebo 6 [0,21 %]) prišlo v 30 dneh po zdravljenju.
English: Psychiatric scales showed no differences between the varenicline and placebo groups and no overall worsening of depression, or other psychiatric symptoms, during the study in either treatment group.
Slovenian: Pri psihiatričnih lestvicah ni bilo razlik med skupinama, ki sta prejemali vareniklin in placebo, ali splošnega poslabšanja depresije pri katerikoli izmed skupin v času trajanja študije.
English: UNIQUE IDENTIFIER - 2D BARCODE Not Applicable
Slovenian: EDINSTVENA OZNAKA - DVODIMENZIONALNA ČRTNA KODA
English: It is preferable to avoid the use of CHAMPIX while you are pregnant.
Slovenian: Med nosečnostjo se je zdravilu CHAMPIX bolje izogibati.
English: Bottles: 2 years Blisters: 3 years
Slovenian: Pretisni omoti: 3 leta.
English: Varenicline (N=1130)
Slovenian: vareniklin (n = 1.130)
English: Subjects aged 18-75 years, smoking 10 or more cigarettes per day were randomised 1:1:1:1 to varenicline 1 mg BID, bupropion SR 150 mg BID, nicotine replacement therapy patch (NRT) 21 mg/day with taper or placebo for a treatment period of 12 weeks; they were then followed for another 12 weeks post-treatment.
Slovenian: Preskušance, stare 18-75 let, ki so pokadili 10 ali več cigaret na dan, so randomizirali v razmerju 1:1:1:1 v skupino, ki je prejemala vareniklin 1 mg dvakrat na dan, v skupino, ki je prejemala bupropion SR 150 mg dvakrat na dan, v skupino z nadomestnim zdravljenjem z nikotinskim obližem (NRT) 21 mg/dan s postopnim zmanjševanjem, ali v skupino s placebom za 12-tedensko obdobje zdravljenja; nato so jih spremljali še nadaljnjih 12 tednov po zdravljenju.
English: In subjects with severe renal impairment (estimated creatinine clearance < 30 ml/min), varenicline exposure was increased 2.1-fold.
Slovenian: Pri preskušancih s hudo okvaro ledvic (ocenjeni očistek kreatinina < 30 ml/min) je bila izpostavljenost vareniklinu 2,1-krat večja.
English: Nonclinical data indicate varenicline has reinforcing properties albeit with lower potency than nicotine.
Slovenian: Predklinični podatki kažejo, da ima vareniklin okrepitvene učinke, čeprav so le-ti manj močni kot pri nikotinu.
English: Seizure, tremor, lethargy, hypoaesthesia
Slovenian: Občasni epileptični napad, tremor, letargija, hipestezija
English: CHAMPIX is not recommended for use in paediatric patients because its efficacy in this population was not demonstrated (see sections 5.1 and 5.2).
Slovenian: Uporaba zdravila CHAMPIX pri pediatričnih bolnikih ni priporočljiva, ker njegova učinkovitost pri tej populaciji ni bila dokazana (glejte poglavji 5.1 in 5.2).
English: Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, fertility and embryo-foetal development.
Slovenian: Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti, plodnosti in embriofetalnega razvoja ne kažejo posebnega tveganja za človeka.